@article {Blanco-Mavillard2020.09.04.20187989, author = {Ian Blanco-Mavillard and Gaizka Parra-Garc{\'\i}a and Ismael Fern{\'a}ndez-Fern{\'a}ndez and Miguel {\'A}ngel Rodr{\'\i}guez-Calero and Celia Personat-Labrador and Enrique Castro-S{\'a}nchez}, title = {CARE OF PERIPHERAL INTRAVENOUS CATHETERS IN THREE HOSPITALS IN SPAIN: MAPPING CLINICAL OUTCOMES AND IMPLEMENTATION OF CLINICAL PRACTICE GUIDELINES}, elocation-id = {2020.09.04.20187989}, year = {2020}, doi = {10.1101/2020.09.04.20187989}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background Peripheral intravenous catheters (PIVCs) are the most widely used invasive devices worldwide. Up to 42\% of PIVCs are prematurely removed during intravenous therapy due to failure. To date, there have been few systematic attempts in European hospitals to measure adherence to recommendations to mitigate PIVC failures.Aim To analyse the clinical outcomes from clinical practice guideline recommendations for PIVC care on different hospital types and environments.Methods We conducted an observational study in three hospitals in Spain from December 2017 to April 2018. The adherence to recommendations was monitored via visual inspection in situ evaluations of all PIVCs inserted in adults admitted. Context and clinical characteristics were collected by an evaluation tool, analysing data descriptively.Results 646 PIVCs inserted in 624 patients were monitored, which only 52.7\% knew about their PIVC. Regarding PIVC insertion, 3.4\% (22/646) patients had at least 2 PIVCs simultaneously. The majority of PIVCs were 20G (319/646; 49.4\%) and were secured with transparent polyurethane dressing (605/646; 93.7\%). Most PIVCs (357/646; 55.3\%) had a free insertion site during the visual inspection at first sight. We identified 342/646 (53\%) transparent dressings in optimal conditions (clean, dry, and intact dressing). PIVC dressings in medical wards were much more likely to be in intact conditions than those in surgical wards (234/399, 58.7\% vs. 108/247, 43.7\%). We identified 55/646 (8.5\%) PIVCs without infusion in the last 24 hours and 58/646 (9.0\%) PIVCs without infusion for more than 24 hours. Regarding PIVC failure, 74 (11.5\%) adverse events were identified, all of them reflecting clinical manifestation of phlebitis.Conclusions Our findings indicate that the clinical outcome indicators from CPG for PIVC care were moderate, highlighting differences between hospital environments and types. Also, we observed that nearly 50\% of patients did not know what a PIVC is.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by The College of Nurses of the Balearic Islands under grant number PI2017/0192. The findings and conclusions in this study are those of the authors and do not necessarily represent the official positions of The College of Nurses of the Balearic Islands. Enrique Castro-Sanchez is also an NIHR Senior Nurse and Midwife Research Leader, and recognises the support of the NIHR Imperial Patient Safety Translational Research Centre and the BRC.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The research ethic committee of Hospital Manacor and Balearic Islands approved this study (IB3492/17PI). All patients were informed about the purpose of the study and their implications. We obtained oral consent from patients or their legal guardian (in the case of patients with cognitive impairment) before study participation. Patients who accepted to participate in the study were progressively included during the study period. No patient refused to participate in the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets analysed during the current study are available from the corresponding author on a request from group investigation.List of abbreviationsPIVCPeripheral intravenous catheter;CRBSIcatheter-related bloodstream infection;CPGClinical practice guideline.}, URL = {https://www.medrxiv.org/content/early/2020/09/05/2020.09.04.20187989}, eprint = {https://www.medrxiv.org/content/early/2020/09/05/2020.09.04.20187989.full.pdf}, journal = {medRxiv} }